Citadel Advisors
CYCN

Citadel Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Citadel Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$868 – 14459
2023
Q1 		$868 Sell
100
-20
-17% -$252 ﹤0.01% 14406
2022
Q4 		$1.57K Buy
+120
New +$1.42K ﹤0.01% 14450
2022
Q1 		– Sell
-1,790
Closed -$62K – 13734
2021
Q4 		$62K Sell
1,790
-890
-33% -$42K ﹤0.01% 13119
2021
Q3 		$165K Sell
2,680
-2,380
-47% -$156K ﹤0.01% 12239
2021
Q2 		$395K Buy
+5,060
New +$317K ﹤0.01% 10594

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's CYCN Position: Q2 2026 in Review

Citadel Advisors increased its Cyclerion Therapeutics (CYCN) stake by 227% in Q2 2026, buying an estimated $135K and bringing the position to 59,795 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #12043.

Citadel Advisors first reported a position in CYCN in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.42M in Q2 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Citadel Advisors held 59,795 shares of Cyclerion Therapeutics worth $203K as of Q2 2026.
  • Citadel Advisors bought 41,534 Cyclerion Therapeutics shares in Q2 2026, an estimated $135K.
  • Cyclerion Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12043 holding.
  • Citadel Advisors first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 9 quarters since.
  • Citadel Advisors's Cyclerion Therapeutics position peaked at $3.42M in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.